Genta

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 21, 2022
BCMA, Rachel Haurwitz, Private Securities Litigation Reform Act, AML, TRAC, Research, AbbVie, Celgene, Genome, Type 2, Association, Technology, B2M, Nasdaq, Pharming, GLOBE, Series, Bristol Myers Squibb, Efficiency, Annual report, CRISPR, Security (finance), Drug development, Risk, American Association, MM, G&A, Cell, Annual general meeting, U.S. Securities and Exchange Commission, Income, IPO, Lymphatic system, DNA, Clinical trial, AACR, Immunity, Multiple myeloma, MED, American Association for Cancer Research, Phenotype, NK, Patient, Merck, Company, CRISPR/Cpf1, IND, CAR, Novartis, RNA, PD-1, Genta, Pharmaceutical industry, Management, Vaccine, Animal, Sewing, Pharmacology, Reindeer

BERKELEY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported business highlights and financial results for the fourth quarter and full year 2021.

Key Points: 
  • Since the beginning of 2021, Caribou has welcomed three new members of the executive leadership team.
  • In addition to Dr. Rizvi, Ruhi Khan joined as chief business officer, and Jason OByrne joined as chief financial officer.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
  • Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Rgenta Therapeutics Enters into a Collaboration with Lundbeck

Retrieved on: 
Wednesday, August 4, 2021
Lundbeck, Valby, Genta, Companies, Economy of Denmark, Industry economics)

Under the collaboration agreement, Rgenta will use its novel and integrative discovery platform to identify and optimize RNA-targeting small molecules against high-value targets.

Key Points: 
  • Under the collaboration agreement, Rgenta will use its novel and integrative discovery platform to identify and optimize RNA-targeting small molecules against high-value targets.
  • Rgenta will grant Lundbeck the option to exclusively license the candidate molecules, which will be developed and commercialized by Lundbeck.
  • In addition, Rgenta is eligible to receive tiered royalties on global net sales of products resulting from the collaboration.
  • Lundbeck and Rgenta may elect to expand the partnership to include other brain disease targets for additional consideration.

Global Brain Metastases Clinical Trial Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Health, Clinical trials, Health sciences, Drug discovery, Health, Pharmaceutical industry, Clinical research, Life sciences, Design of experiments, Clinical trial, YM Biosciences, Genta

The "Global Brain Metastases Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Brain Metastases Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Brain Metastases Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Brain Metastases market.
  • It covers emerging therapies for Brain Metastases in active clinical development stages including early and late stage clinical trials.
  • The report provides Brain Metastases pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Traumatic Brain Injury Recovery

Retrieved on: 
Monday, May 31, 2021
Health sciences, Clinical research, Health, Food and Drug Administration, Drug Safety, Investigational New Drug, Pharmaceutical industry, Moleac, Criticism of the Food and Drug Administration, Genta

SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI).

Key Points: 
  • SINGAPORE, May 31, 2021 /PRNewswire/ -- Moleac, a biopharmaceutical company based in Singapore, announced the approval by the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for MLC1501 in traumatic brain injury (TBI).
  • The approval of this IND comes 3 years after the opening of the first IND by the U.S. FDA for MLC1501 in Post-Stroke Recovery, allowing Moleac to conduct a phase 1 study (safety study) in healthy volunteers which has been successfully completed.
  • "This approval represents another milestone for Moleac, supporting our ambition to provide best in class therapeutic options to patients in need.
  • In 2018, the U.S. FDA has approved an IND for MLC1501 in post-stroke recovery, the phase 1 was completed in 2020.

Rgenta Therapeutics Announces the Successful Completion of Extension of Seed Financing

Retrieved on: 
Tuesday, May 25, 2021
Genta

Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets.

Key Points: 
  • Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets.
  • "We believe Rgenta has assembled a winning team to realize the potential of this novel modality."
  • BIVF, Matrix Capitals co-led the initial seed round with other early investors in 2020.
  • Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Retrieved on: 
Tuesday, May 25, 2021
Medicine, Clinical medicine, Orphan drugs, Drugs, Chronic lymphocytic leukemia, Tyrosine kinase inhibitors, Antineoplastic drugs, Leukemia, CLL, Fast track, Progression-free survival, Genta

The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss this application.

Key Points: 
  • The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss this application.
  • FDA previously granted Fast Track designation to the combination of ublituximab and UKONIQ for the treatment of adult patients with CLL and orphan drug designation for ublituximab in combination with UKONIQ for the treatment of CLL.
  • The primary endpoint for this study was superior progression-free survival (PFS) for the U2 combination compared to the control arm.
  • Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia.

TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia

Retrieved on: 
Monday, March 29, 2021
Food and Drug Administration, Fast track, Life sciences, CLL, Chronic lymphocytic leukemia, FDA Special Protocol Assessment, Leukemia, Clinical medicine, Medicine, Genta, P110δ

The trial met its primary endpoint and results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2020.

Key Points: 
  • The trial met its primary endpoint and results were presented at the American Society of Hematology (ASH) Annual Meeting in December 2020.
  • The UNITY-CLL Phase 3 trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
  • Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia.
  • A drug that receivesFast Trackdesignation is eligible for more frequent interactions with the FDA, priority review if relevant criteria are met, and rolling submission of the Biologics License Application or New Drug Application.

Small Molecule Cancer Drug Market USD 125 Billion Opportunity

Retrieved on: 
Thursday, March 25, 2021
Clinical medicine, Medicine, Cancer, Antineoplastic drugs, Oncology, Chemotherapy, Occupational safety and health, Small molecule, Bemcentinib, Genta

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:
    Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
    USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
    Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    Small molecule cancer drugs for the patients are considered to be among the top-notch discoveries ever made by the oncology researchers.
  • Amid the availability of specific therapies in the cancer therapeutics market that are old and traditional as well as are associated with large number of drugs and agents, the overall market availability of small molecule cancer drugs is believed to make the entire cancer therapeutics market undergo significant revolution.
  • As per "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report findings, it is estimated that the market over the past few years have landed with large number of agents capable of targeting the cancerous cells and ultimately causing eradication of the cancer cells from the human body.
  • The overall change in the dynamics of the therapy is believed to be due to the arrival of small molecule cancer drug market.

Small Molecule Cancer Drug Market USD 125 Billion Opportunity

Retrieved on: 
Thursday, March 25, 2021
Clinical medicine, Medicine, Cancer, Antineoplastic drugs, Oncology, Chemotherapy, Occupational safety and health, Small molecule, Bemcentinib, Genta

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:
    Small Molecule Cancer Drug Market Opportunity: More Than US$ 125 Billion by 2026
    USA Dominates The Global Small Molecule Cancer Drug Market: >50% Share
    Small Molecule Cancer Drug Market Clinical Trials: >2500 Drugs
    Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs
    Clinical Trials Insight by Phase, Company, Country, Formulation, Indication
    Small molecule cancer drugs for the patients are considered to be among the top-notch discoveries ever made by the oncology researchers.
  • Amid the availability of specific therapies in the cancer therapeutics market that are old and traditional as well as are associated with large number of drugs and agents, the overall market availability of small molecule cancer drugs is believed to make the entire cancer therapeutics market undergo significant revolution.
  • As per "Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report findings, it is estimated that the market over the past few years have landed with large number of agents capable of targeting the cancerous cells and ultimately causing eradication of the cancer cells from the human body.
  • The overall change in the dynamics of the therapy is believed to be due to the arrival of small molecule cancer drug market.

SHAREHOLDER ALERT: Robbins LLP Reminds Shareholders that Athenex, Inc. (ATNX) is Being Sued for Misleading Shareholders

Retrieved on: 
Wednesday, March 24, 2021
Legal, Professional services, Carbonyl compounds, Drugs, Oxygen compounds, Taxanes, Benzamides, Bristol-Myers Squibb, Paclitaxel, New Drug Application, Genta, Neurocrine Biosciences

Athenex is a global clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next generation drugs for the treatment of cancer.

Key Points: 
  • Athenex is a global clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next generation drugs for the treatment of cancer.
  • One of the Company's main drug candidates is an oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
  • If you suffered a loss due to Athenex, Inc.'s misconduct, click here .
  • The Company stated that it was preparing its New Drug Application ("NDA") for submission to the Federal Drug Administration ("FDA") and touted their Study over the next several months.